367 related articles for article (PubMed ID: 18504579)
21. Glucarpidase following high-dose methotrexate: update on development.
Patterson DM; Lee SM
Expert Opin Biol Ther; 2010 Jan; 10(1):105-11. PubMed ID: 19925307
[TBL] [Abstract][Full Text] [Related]
22. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
24. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
Scott JR; Zhou Y; Cheng C; Ward DA; Swanson HD; Molinelli AR; Stewart CF; Navid F; Jeha S; Relling MV; Crews KR
Pediatr Blood Cancer; 2015 Sep; 62(9):1518-22. PubMed ID: 25631103
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
Fukuhara K; Ikawa K; Morikawa N; Kumagai K
J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
[TBL] [Abstract][Full Text] [Related]
26. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
[TBL] [Abstract][Full Text] [Related]
27. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
28. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
O'Brien PC; Roos DE; Pratt G; Liew KH; Barton MB; Poulsen MG; Olver IN; Trotter GE;
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):408-13. PubMed ID: 16198065
[TBL] [Abstract][Full Text] [Related]
29. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
30. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
31. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
32. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R
Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
34. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
[TBL] [Abstract][Full Text] [Related]
35. Mobilization of hemopoietic stem cells with high-dose methotrexate plus granulocyte-colony-stimulating factor in patients with primary central nervous system lymphoma.
Kiefer T; Krüger WH; Montemurro M; Schüler F; Hirt C; Pasold R; Niederwieser D; Schwenke M; Dölken G
Transfusion; 2008 Dec; 48(12):2624-8. PubMed ID: 18801020
[TBL] [Abstract][Full Text] [Related]
36. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
37. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
38. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
[TBL] [Abstract][Full Text] [Related]
39. [The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate].
Blasco H; Silly S; Tournamille JF; Gyan E; Sénécal D; André V; Colombat P; Le Guellec C
Therapie; 2008; 63(1):19-28. PubMed ID: 18387272
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate nephrotoxicity: Novel treatment, new approach.
Iqbal S; Armaghani A; Aiyer R; Kazory A
J Oncol Pharm Pract; 2013 Dec; 19(4):373-6. PubMed ID: 24255083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]